Search

for
Search:

Community Join

5 / 1000+ results

community Pyrilutamide phase III clinical trial results released

in Research/Science 31 upvotes 2 years ago

Pyrilutamide did not show effectiveness in regrowing hair compared to a placebo, but it may still help maintain existing hair by preventing DHT from causing follicle miniaturization. Some users believe it could be beneficial when used with other treatments like minoxidil, finasteride, and dutasteride.

community What the Breezula Phase III results mean & realistic timeline

59 upvotes 9 months ago

Breezula offers modest hair growth similar to finasteride and is expected to be available by late 2026. It is a safe alternative without hormonal side effects and works well with minoxidil.

community Breezula 6 Month Topline Phase III Results Released

172 upvotes 9 months ago

Breezula shows promising hair growth results, with up to 539% increase in hair count compared to placebo, and regulatory submissions are planned in the US and EU. Users are cautiously optimistic, noting the potential for Breezula to replace finasteride by targeting DHT without systemic effects.

community So why did the first pyrilutamide phase III fail?

4 upvotes 1 month ago

Pyrilutamide's inconsistent trial results, with phase II showing positive hair growth and phase III failing to show significant gains, possibly due to COVID-related disruptions. Users discuss modest results from kx-826 treatment.

community Pelage to present PP405 Phase 2a clinical trial full results at an upcoming medical meeting - CMO Christina Weng says

748 upvotes 8 months ago

Pelage is moving to Phase III clinical trials for PP405, a hair loss treatment, with results to be presented at a medical meeting. Users express skepticism and hope, comparing it to existing treatments like Minoxidil and finasteride, while discussing the potential for new hair growth in previously bald areas.

View more "phase iii results" in community →

Research

5 / 1000+ results

research Acne Resolution Rates: Results of a Single-Blind, Randomized, Controlled, Parallel Phase III Trial with EE/CMA (Belara^®) and EE/LNG (Microgynon^®)

88 citations , January 2001 in “Dermatology”

This study found that the monophasic oral contraceptive ethinylestradiol/chlormadinone acetate was more effective in treating mild to moderate papulopustular acne in women than ethinylestradiol/levonorgestrel.

research Impact of ustekinumab on quality of life and sexual difficulties associated with psoriasis: Results from phase III clinical trials

February 2010 in “Journal of The American Academy of Dermatology”

This study found that nonobese women with idiopathic hirsutism exhibited lower nitrite/nitrate concentrations and higher fibrinogen levels compared to control subjects, but these were similar to levels in women with polycystic ovary syndrome.

research Efficacy of autologous dermal sheath cup cell transplantation in male and female pattern hair loss: A Single‐Arm, Multi‐Center, phase III equivalent clinical study

September 2023 in “The Journal of Dermatology”

In this study, injecting dermal sheath cup cells into affected areas of pattern hair loss improved hair thickness and patient-reported hair appearance in 62.9% of the participants, with better results in women, without serious side effects.

research Correction to “Efficacy of Autologous Dermal Sheath Cup Cell Transplantation in Male and Female Pattern Hair Loss: A Single‐Arm, Multi‐Center, Phase III Equivalent Clinical Study”

January 2026 in “The Journal of Dermatology”

This clinical study reported on autologous dermal sheath cup cell transplantation for male and female pattern hair loss, with no new efficacy results included in this correction notice.

research Effects of Dehydroepiandrosterone Therapy on Pubic Hair Growth and Psychological Well-Being in Adolescent Girls and Young Women with Central Adrenal Insufficiency: A Double-Blind, Randomised, Placebo-Controlled Phase III Trial

February 2009 in “Endocrinology”

This study evaluated the use of oral DHEA for treating atrichia pubis and psychological distress in young females with central adrenal insufficiency but reports no new results.

View more "phase iii results" in research →

Learn

6 / 800 results

learn Pyrilutamide

What is pyrilutamide, and how does it help with androgenic alopecia or hair loss caused by DHT? Pyrilutamide (KX-826) is an investigational topical antiandrogen designed to block DHT at the androgen receptor in the scalp rather than lower DHT in the blood. Its sponsor has announced positive Phase III top-line results in China, but none of the data are peer-reviewed and it is not approved as a medicine anywhere.

learn Clascoterone

Is clascoterone suitable for both men and women? Clascoterone is not approved for hair loss in either sex — the approved product is a 1% acne cream. The scalp version has completed phase III trials in men with sponsor-reported positive results; in women the only data is a company-reported phase II significant in one subgroup, so use is off-label and investigational for both.

learn Osteopontin

signaling protein that, when suppressed, may grow hair by reducing inflammation and stem cell loss

learn Finasteride

Prescription tablet (1 mg) that slowed hair loss versus placebo in two-year trials. Labels warn of sexual side effects that have continued after stopping, and of depression and suicidal thoughts; not for use in pregnancy.

learn Hair Multiplication

extract, clone, and reinsert your own hair cells

learn GT20029

When will GT20029 be commercially available, and are there any clinical trials on its use? GT20029 is not approved or commercially available anywhere and remains investigational. A published 12-week Phase II study in 180 Chinese men reports hair-count gains over placebo, but no long-term or Phase III data exists, so any launch is years away at best.

View more "phase iii results" in learn →

Clinics

5 / 5 results

Experts

— no results

Try a deeper search in experts →